Carterra’s new research collaboration with AstraZeneca (LSE:AZN) on lab in the loop drug discovery has put the pharmaceutical group’s AI ambitions in sharper focus for investors watching the stock.
AstraZeneca’s recent AI and oncology announcements arrive after a mixed year for holders, with the share price at £119.98 and a year to date share price return declining 11.73%, even though the 5 year total shareholder return of 51.39% points to a stronger longer run record.
Scan a handpicked set of healthcare AI stocks that reflect AstraZeneca’s focus on lab-in-the-loop discovery with the 7 healthcare AI stocks.
AstraZeneca is pushing hard into AI and oncology while the share price has fallen this year. So do you take that setup now, or wait for a lower entry and cheaper valuation metrics to blink first?
Most Popular Narrative: 25% Undervalued
AstraZeneca’s most followed valuation narrative pegs fair value at £159.11, compared with the last close at £119.98, which sets up a clear gap that hinges on how investors view oncology, rare disease assets, and the impact of AI on R&D productivity.
The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular/metabolic therapies, is set to deliver multiple blockbuster launches over the next several years. Management estimates these new medicines could generate $10+ billion in peak risk-adjusted revenue, directly supporting both long-term high-margin revenue growth and future earnings expansion.
See why 209 investors see AstraZeneca as 25% undervalued.
Result: Fair Value of £159.11 (UNDERVALUED)
Still, AstraZeneca’s reliance on a handful of blockbuster therapies and rising exposure to government price controls could quickly challenge the bullish valuation story.
Find out about the key risks to this AstraZeneca narrative.
Next Steps
If this mix of optimism and concern around AstraZeneca leaves you undecided, move quickly to weigh both sides and focus on the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond AstraZeneca?
Do not stop at AstraZeneca. Use the Simply Wall Street Screener to spot fresh opportunities that fit your goals before the market prices them differently.
- Target higher potential upside by focusing on companies that combine quality with attractive valuations through the 7 high quality undervalued stocks.
- Strengthen your income stream by zeroing in on reliable high-yield payers using the 1 dividend fortresses.
- Guard against shocks by concentrating on resilient businesses with robust finances through the 4 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com